Home
Storia in 4 fonti
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition
- ·
cnbc.com
Novo Nordisk tumbles 11% after forecasting sales declines this year
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
- ·
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling.
- ·
cincodias.elpais.com
Las acciones de Novo Nordisk se desploman ante la previsión de una fuerte caída de las ventas de Ozempic y Wegovy este año
La compañía danesa baja hasta un 20%, la mayor caída desde julio pasado al anunciar un recorte del 13% en la facturación para 2026
- ·
theguardian.com
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition
- ·
bbc.com
Wegovy-maker Novo Nordisk warns of 'painful' price cuts as shares slump
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.